Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nature Reviews. Cancer

• Publication date

  2007-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc2152PMID 17522716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Similarities and Differences

  2008cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

  2007cited by this paper
• XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)

  2007cited by this paper
• Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer

  2007cited by this paper
• 3048 POSTER Safety and effectiveness of bevacizumab (BV) plus chemotherapy (CT) in elderly patients with mCRC: results from the BRiTE registry

  2007cited by this paper
• Mechanisms of Cancer-Induced Thrombosis in Cancer

  2006cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Flow effects on coagulation and thrombosis.

  2006cited by this paper
• Predicting benefit from anti-angiogenic agents in malignancy

  2006cited by this paper
• Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.

  2006cited by this paper
• Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP.

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome and bevacizumab.

  2006cited by this paper
• AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

  2006cited by this paper
• Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome and bevacizumab.

  2006cited by this paper
• Primary carcinoid tumor in an ileal conduit.

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

  2006cited by this paper
• The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis

  2006cited by this paper
• Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling.

  2006cited by this paper
• Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis.

  2006cited by this paper
• KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium.

  2006cited by this paper
• The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

  2006cited by this paper
• Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma

  2006cited by this paper
• An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

  2006cited by this paper
• Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

  2006cited by this paper
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer

  2006cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• Different Effects of Amlodipine and Enalapril on the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase–Extracellular Signal-Regulated Kinase Pathway for Induction of Vascular Smooth Muscle Cell Differentiation In Vivo

  2006cited by this paper
• Sunitinib malate for the treatment of solid tumours: a review of current clinical data

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Long-term response with sunitinib for metastatic renal cell carcinoma.

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• BAY 43-9006 inhibition of oncogenic RET mutants.

  2006cited by this paper
• Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

  2006cited by this paper
• Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.

  2006cited by this paper
• A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice

  2006cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases.

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Angiogenesis inhibitors and hypertension: an emerging issue.

  2006cited by this paper
• Targeting Angiogenesis in Cancer: Bevacizumab-Induced Platelet Activation as a Possible Cause for Unexpected Arterial Thromboembolic Events in Clinical Trials.

  2006cited by this paper
• Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

  2005cited by this paper
• Maximizing Ventricular Function With Multimodal Cell-Based Gene Therapy

  2005cited by this paper
• Cutaneous side-effects of kinase inhibitors and blocking antibodies.

  2005cited by this paper
• Angiogenesis as a therapeutic target

  2005cited by this paper
• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

  2005cited by this paper
• Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

  2005cited by this paper
• In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.

  2005cited by this paper
• Inhibition of angiogenesis in cancer patients

  2005cited by this paper
• Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

  2005cited by this paper
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

  2005cited by this paper
• Investigation of Vascular Responses in Endothelial Nitric Oxide Synthase/Cyclooxygenase-1 Double-Knockout Mice: Key Role for Endothelium-Derived Hyperpolarizing Factor in the Regulation of Blood Pressure in Vivo

  2005cited by this paper
• Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

  2005cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.

  2005cited by this paper
• Cancer without disease

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice

  2004cited by this paper
• Cancer‐related fatigue: Evolving concepts in evaluation and treatment

  2004cited by this paper
• Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?

  2004cited by this paper
• Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies

  2004cited by this paper
• Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias

  2004cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Angiogenic growth factors and hypertension

  2004cited by this paper
• Expression of vascular endothelial growth factor protein in human renal cell carcinoma

  2004cited by this paper
• Relationship between platelet count and bleeding risk in thrombocytopenic patients.

  2004cited by this paper
• ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.

  2004cited by this paper
• The functional role of blood platelet components in angiogenesis

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

  2004cited by this paper
• A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

  2003cited by this paper
• Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria*

  2003cited by this paper
• Ectopic pregnancy rates with day 3 versus day 5 embryo transfer: a retrospective analysis

  2003cited by this paper
• Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

  2003cited by this paper
• Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

  2003cited by this paper
• Imatinib mesylate causes hypopigmentation in the skin

  2003cited by this paper
• Bevacizumab, bleeding, thrombosis, and warfarin.

  2003cited by this paper
• Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Histological analysis of defective colonic healing as a result of angiostatin treatment.

  2003cited by this paper
• Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Fundamental concepts of the angiogenic process.

  2003cited by this paper
• Capillary rarefaction and abnormal cardiovascular reactivity in hypertension

  2003cited by this paper
• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  2003cited by this paper
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

  2002cited by this paper
• Mechanisms of Anti-Angiogenic Tyrosine Kinase Inhibition on Wound Healing: The Obvious and Not So Obvious

  2002cited by this paper
• Identification of functional VEGF receptors on human platelets

  2002cited by this paper
• Exaggerated Hypotensive Effect of Vascular Endothelial Growth Factor in Spontaneously Hypertensive Rats

  2002cited by this paper
• SU5416 delays wound healing through inhibition of TGF-beta 1 activation.

  2002cited by this paper

• Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives.

  2026cites this paper
• Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  2026cites this paper
• The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib

  2026cites this paper
• Buccodental Toxicities Induced by Tyrosine Kinase Inhibitors in Patients Diagnosed with Renal Cell Carcinoma—A Literature Review

  2025cites this paper
• Embryonic reprogramming of the tumor vasculature reveals targets for cancer therapy

  2025cites this paper
• Empagliflozin attenuates sorafenib-promoted renal ferroptosis and inflammation by targeting cyclooxygenase-2/prostaglandin E2 axis.

  2025cites this paper
• Small-Molecule Trk Agonists: Where Do We Go from Here?

  2025cites this paper
• Inhibition of pathological angiogenesis in oxygen-induced retinopathy by arginine depletion with ADI-PEG20.

  2025cites this paper
• Risk factors for the exacerbation of esophageal varices in patients receiving atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma.

  2025cites this paper
• The FKBPL-based therapeutic peptide, AD-01, protects the endothelium from hypoxia-induced damage by stabilising hypoxia inducible factor-α and inflammation

  2025cites this paper
• Fatal portal vein thrombosis following combination therapy with atezolizumab plus bevacizumab for hepatocellular carcinoma: an autopsy case report

  2025cites this paper
• Drug-drug interactions in anticoagulant therapy: a focus on oncology patients

  2025cites this paper
• Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma

  2025cites this paper
• Myeloid ACAT1/SOAT1: a novel regulator of dyslipidemia and retinal neovascularization

  2025cites this paper
• Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?

  2025cites this paper
• Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy

  2024cites this paper
• An Overview of Cancer Biology, Pathophysiological Development and It’s Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy

  2024cites this paper
• Discovery of Novel Pyrimidine Based Small Molecule Inhibitors as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-Cancer Studies.

  2024cites this paper
• Comprehensive analysis of nationwide anticancer drug-related complications in Korea: incidence, types, and cancer-specific considerations in contemporary oncology

  2024cites this paper
• Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants

  2024cites this paper
• Nature's Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.

  2024cites this paper
• Angiogenesis in Breast Cancer: A Review

  2024cites this paper
• Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy

  2024cites this paper
• Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database

  2024cites this paper
• The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line

  2024cites this paper
• Curcumol Attenuates Portal Hypertension and Collateral Shunting Via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats

  2024cites this paper
• CACA guidelines for holistic integrative management of nasopharyngeal carcinoma

  2023cites this paper
• Emerging nanotechnological approaches to regulating tumor vasculature for cancer therapy.

  2023cites this paper
• Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System

  2023cites this paper
• Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles

  2023influential citation
• The apoptotic, inflammatory, and fibrinolytic actions of vasoinhibin are in a motif different from its antiangiogenic HGR motif

  2023influential citation
• Downregulation of VEGFR2 signaling by cedrol abrogates VEGF‑driven angiogenesis and proliferation of glioblastoma cells through AKT/P70S6K and MAPK/ERK1/2 pathways

  2023cites this paper
• Vasoinhibin’s Apoptotic, Inflammatory, and Fibrinolytic Actions Are in a Motif Different From Its Antiangiogenic HGR Motif

  2023cites this paper
• Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report

  2022cites this paper
• Concurrent hemoptysis and pulmonary embolism associated with lenvatinib therapy for unresectable thymic carcinoma: A case report

  2022cites this paper
• Received anti-VEGF therapy in a patient with CRAO sparing the CLRA with subretinal fluid: A case report

  2022cites this paper
• Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice

  2022cites this paper
• Maintaining functional status among older adult cancer patients and survivors

  2022cites this paper
• Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms.

  2021cites this paper
• Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease.

  2021cites this paper
• Surface Modification with NGF-Loaded Chitosan/Heparin Nanoparticles for Improving Biocompatibility of Cardiovascular Stent

  2021cites this paper
• Visualization of Kinase Inhibition-Related Adverse Events Using the Japanese Adverse Drug Event Report Database

  2021cites this paper
• Bevacizumab

  2021cites this paper
• Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New York

  2021cites this paper
• CT imaging findings of lenvatinib-induced enteritis

  2021cites this paper
• Bowel Perforation During Haemophagocytic Lymphohistiocytosis Treatment with Corticosteroids and Anakinra.

  2021cites this paper
• Nephrotoxicity of Anti-Angiogenic Therapies

  2021cites this paper
• Management of VEGFR-Targeted TKI for Thyroid Cancer

  2021cites this paper
• Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report

  2021cites this paper
• Atherosclerosis, Ischemia, and Anticancer Drugs

  2021cites this paper
• Incidence and computed tomography findings of lenvatinib-induced pancreatobiliary inflammation

  2021cites this paper
• Repurposing Erythrocytes as a "Photoactivatable Bomb": A General Strategy for Site-Specific Drug Release in Blood Vessels.

  2021cites this paper
• An innovation idea for SBLOCA mitigation strategy: Self-coagulation system in comparison with human hemostatic mechanism

  2021cites this paper
• Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein

  2021cites this paper
• Targeted silencing of TEM8 suppresses non-small cell lung cancer tumor growth via the ERK/Bcl-2 signaling pathway

  2021cites this paper
• Tumor Microenvironment

  2020cites this paper
• [Retinal arterial macroaneurysm and anti-Vascular Endothelial Growth Factor (aflibercept) in Eales's disease: A case report].

  2020cites this paper
• Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparin

  2020cites this paper
• Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

  2020cites this paper
• Ilimaquinone inhibits neovascular age-related macular degeneration through modulation of Wnt/β-catenin and p53 pathways.

  2020cites this paper
• Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment

  2020cites this paper
• To treat or not to treat: a clinical series of retinal arterial macroaneurysms

  2020cites this paper
• Lectin from Laetiporus sulphureus effectively inhibits angiogenesis and tumor development in the zebrafish xenograft models of colorectal carcinoma and melanoma.

  2020cites this paper
• Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer

  2020cites this paper
• Multiple retinal vein thromboses after intravitreal aflibercept injections for age‐related macular degeneration

  2020cites this paper
• Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy

  2020cites this paper
• Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life

  2020cites this paper
• Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study

  2020cites this paper
• Ephrin-A5 Is Involved in Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy

  2020cites this paper
• Ultra high dose rate Synchrotron Microbeam Radiation Therapy. Preclinical evidence in view of a clinical transfer.

  2019cites this paper
• Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1- a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links.

  2019cites this paper
• Risk Factor and Biomarker of Preeclampsia

  2019cites this paper
• N-Terminal modification of the tetrapeptide Arg-Leu-Tyr-Glu, a VEGFR-2 antagonist, improves anti-tumor activity by increasing its stability against serum peptidases

  2019influential citation
• Biologic and Therapeutic Studies to Improve the Anti-tumor Efficacy of Antiangiogenic Tyrosine Kinase Inhibitors

  2019cites this paper
• Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer

  2019cites this paper
• Monoclonal Antibodies in Cancer

  2019cites this paper
• Controversial roles for dexamethasone in glioblastoma – Opportunities for novel vascular targeting therapies

  2019cites this paper
• Inhibition of angiogenesis and tumor growth by a novel 1,4‐naphthoquinone derivative

  2019cites this paper
• Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

  2019cites this paper
• Advances in toxicity risk analysis and effective treatments for targeted antiangiogenic drugs

  2019cites this paper
• Rezistentna hipertenzija i centralni krvni tlak

  2019cites this paper
• Role of the Angiogenic Factors in Cholangiocarcinoma

  2019cites this paper
• Design, synthesis, and biological evaluation of tetrahydroisoquinoline-based diaryl urea derivatives for suppressing VEGFR-2 signaling

  2019cites this paper
• Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.

  2019cites this paper
• VEGF Inhibitors Do Not Increase D-dimer Levels in Colorectal Cancer Patients Without Venous Thromboembolism : A Retrospective Non-inferiority Analysis

  2019cites this paper
• Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab

  2019cites this paper
• Wound healing potential of selected Southern African medicinal plants: A review

  2019cites this paper
• ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy

  2019cites this paper
• Design and Synthesis of Pyrimidine Based Heterocycles as Potential Anti-cancer Agents with Combination Chemotherapeutic Potential or Targeted One Carbon Metabolism Inhibition and Anti-opportunistic Agents

  2019cites this paper
• Gold nanoparticles and angiogenesis: molecular mechanisms and biomedical applications

  2019cites this paper
• Identification of Novel Targets for Antiangiogenic Therapy

  2019cites this paper
• Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?

  2019cites this paper
• Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.

  2019cites this paper
• The Role of Anti-Angiogenic Agents (VEGF)

  2019cites this paper
• Discovery of Small Molecules That Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies

  2019cites this paper
• A novel 2‐aminobenzimidazole‐based compound Jzu 17 exhibits anti‐angiogenesis effects by targeting VEGFR‐2 signalling

  2019cites this paper
• N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases

  2019influential citation
• Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy.

  2018cites this paper
• Vaccine Therapy in Pancreatic Cancer

  2018cites this paper
• [Radiological imaging of acute infectious and non-infectious enterocolitis].

  2018cites this paper